Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis by Alavian, Seyed Moayed et al.
KOWSAR
Hepat Mon. 2011;11(8):612-619. DOI: 10.5812/kowsar.1735143X.721
Journal home page: www.HepatMon.com
A
r
t
i
c
l
e
 
O
n
l
i
n
e
 
S
u
b
m
i
s
s
i
o
n
 
a
t
:
W
W
W
.
H
E
P
A
T
M
O
N
.
C
O
M
Number 37, Volume 11, Issue 8, August 2011
Chronic Hepatitis B and C in 
Bosnia
pUb-HBcAg DNA Vaccine 
Enhanced Immune Response
Optimal Duration of Anti-HCV 
Treatment in Genotype 1
LATEST
IMPACT FACTOR
0.793
Official Monthly Journal of the Baqiyatallah Research Center for Gastroenterology and Liver Diseases
ISSN: Print 1735-143x,   Online 1735-3408
Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow 
Responders: A Meta-Analysis 
Seyed Moayed Alavian 
1*, Seyed Vahid Tabatabaei 
1, Bita Behnava 
1, Nastaran Mahboobi 
1
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran
* Corresponding author at: Seyed-Moayed Alavian, Baqiyatallah Research 
Center for Gastroenterology and Liver Diseases, Ground floor of Baqiyatallah 
Hospital, Mollasadra Ave., Vanak Sq. P.O. Box: 14155-3651, Tehran, Iran. Tel/Fax: 
+98-2188067114.
E-mail: editor@hepmon.com
DOI: 10.5812/kowsar.1735143X.721 
Copyright  c 2011, BRCGL, Published by Kowsar M.P.Co.  All rights reserved.
ABSTRACT
Background: A head-to-head comparison of the 72-week and 48-week anti-HCV thera-
pies in slow responders with genotype 1 infection has been performed in several rand-
omized clinical trials (RCTs). 
Objectives: This review aimed at summarizing and pooling the results of these stud-
ies.
Materials and Methods: RCTs that had evaluated the 72-week vs. 48-week anti-HCV ther-
apy (peginterferon and ribavirin) in slow responders with HCV genotype 1 infection 
were systematically identified. A meta-analysis was performed using the random ef-
fects model. Heterogeneity in results was assessed on the basis of the Q statistics, and 
publication bias was evaluated by using Harbord’s modified test. The end point was 
set as a sustained virological response (SVR).
Results: Data of 1206 subjects were retrieved from 7 studies. A total of 631 patients had 
received extended therapy. Slow virological responders who received the 72-week ther-
apy had a significantly higher probability of achieving SVR than their counterparts 
who received the 48-week therapy [RR = 1.44 (95% CI, 1.20–1.73)]. With regard to publi-
cation biases, the heterogeneity in funnel plots was not significant (P = 0.19, I2 = 30%, 
PHarbord = 0.1).
Conclusion: Our meta-analysis showed that the 72-week therapy with peginterferon and 
ribavirin is significantly superior to the standard 48-week therapy in slow responders 
with HCV genotype 1 infection. 
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  Implication for health policy/practice/research/medical education:
Treatment of hepatitis C is associated with eradication of 50% of the cases. Introduction of new methods for treatment of disease by 
increasing the duration of therapy can rise the chance of recovery. This article can be useful for all researchers in the field of gastro-
enterology, infectious disease and virology.
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1. Background
Hepatitis C virus (HCV) infection is a major cause 
of chronic liver disease, cirrhosis, and hepatocellular 
carcinoma (HCC) worldwide, and may necessitate liver 
transplant in the patients with these diseases (1-3). In 80% 
of the cases with HCV infection, the infection progresses 
to  a  chronic  state,  and  in  approximately  20%  of  the 
cases, chronic HCV infection may lead to cirrhosis (4). 
Achievement of a sustained virological response (SVR) 
to antiviral therapy prevents the progression of fibrosis 
and  cirrhosis  and  decreases  the  risk  of  HCC,  thereby 
improving the survival rate of patients. Therefore, 
antiviral therapy is an important treatment option in the 
clinical management of these patients (5-9). 
Currently, the standard therapy for HCV genotype 
1 and genotype 2/3 is administration of regimens of 
peginterferon  alpha  and  ribavirin  for  48  weeks  and Hepat Mon. 2011;11(8):612-619
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24  weeks,  respectively.  Patients  with  rapid  virological 
response  (RVR;  undetectable  HCV-RNA  level  at  week  4 
of therapy) have 80–100% likelihood of achieving SVR, 
whereas those who do not achieve an early virological 
response  (EVR;  undetectable  HCV-RNA  level  at  week 
12 of therapy or less than 2-log decrease in RNA level 
compared to a pretreatment RNA level) have only an 
8% chance of achieving SVR (10, 11). Since viral kinetics 
play an important role during therapy, several studies 
have attempted to evaluate individualized anti-HCV 
therapy on the basis of the patients’ virological response 
instead of HCV genotype alone. In rapid virological 
responders  with  HCV  genotype  2/3  infection,  therapy 
for a duration shorter than that of the standard therapy 
was  as  effective  as  the  standard  therapy;  however,  in 
cases of HCV genotype 1 infection, different results have 
been obtained (12, 13). Several studies have evaluated the 
effects of extending the therapy in slow responders. 
2. Objectives
In  this  review,  we  aimed  to  summarize  and  pool 
the results of these studies to determine the optimal 
duration of treatment for HCV genotype 1 infection in 
slow responders. 
3. Materials and Methods
3.1. Search Methods for Identification of Studies
We performed an electronic search of Medline, EMBASE, 
Scopus, Cochrane Central Register of Controlled Trials, 
and  ISI  Web  of  Knowledge  (SV  Tabatabaei,  B  Behnava). 
The  keywords  we  used  were  different  combinations  of 
“hepatitis  C  virus”  or  “HCV”  with  the  following  terms: 
“slow responders”; “72-week”; “extended therapy”; “rapid 
virological response” or “RVR”; “early  virological  response” 
or “EVR”; “peginterferon alpha-2a”; “peginterferon alpha-
2b”; and “ribavirin” or “RVB” or “RBV”. In addition, terms 
such as “Pegasys,” “Pegintron,” “Rebetol,” and “Copegus” 
were  used.  We  examined  the  references  cited  in  the 
reviewed papers to find other relevant studies. Temporal 
limits were not applied in our search strategy. 
3.2. Data Collection and Analysis
All  citations  were  imported  to  an  EndNote  library. 
Further,  the  titles  and  abstracts  were  screened  by  2 
investigators  (SV  Tabatabaei,  B  Behnava)  who  were 
unaware  of  each  other’s  study  selection.  Full  texts  of 
all  the  selected  reports  were  retrieved  and  assessed 
according  to  our  predefined  inclusion  and  exclusion 
criteria.  Data  from  studies  that  met  our  criteria  were 
extracted by 2 investigators separately and rechecked by 
a third investigator. Data of the outcomes of treatment 
were tabulated according to the treatment regimen in 
Excel  spreadsheets.  Predefined  assumptions  and  the 
decision to include or exclude a study were made and 
agreed by all authors before the meta-analysis. Data on the 
characteristics of patients and studies were summarized 
by using standard questionnaires that included the 
first author’s name, name of journal, methodology of 
randomization, allocation concealment, publication 
year, and sample size in each treatment arm as well as 
viral loads, liver histologies, frequencies of genotypes, 
and SVR.
3.3. End Point of Interest
The  end  point  for  comparison  of  efficacy  was  SVR, 
defined as undetectable HCV-RNA level 6 months after 
treatment cessation.
3.4. Inclusion and Exclusion Criteria
Randomized  clinical  trials  (RCTs)  on  patients  with 
chronic  HCV  infection  who  were  seronegative  for  HIV 
and hepatitis B virus (HBV) infection were included if 
the patients in the trials (1) were randomized to receive 
either  peginterferon  alpha-2a  180  μg/kg  per  week  or 
peginterferon alpha-2b 1.5 μg/kg per week plus weight-
based ribavirin during either the standard (48 weeks) 
or extended therapy (72 weeks), (2) had detectable HCV-
RNA level at week 4 of the treatment, (3) achieved at least 
a 2-log decrease in HCV-RNA levels from the baseline to 
12 weeks or undetectable HCV-RNA at 24 weeks, (4) had 
genotype 1 infection, and (5) were diagnosed with chronic 
HCV infection on the basis of detectable HCV-RNA level 
and infection for at least 6 months. We included articles 
from all languages that met these criteria. Furthermore, 
our meta-analysis included studies that had patients 
with a history of treatment and for whom study dose 
modification  and  administration  of  growth  factors 
and antidepressants were performed. Even the studies 
that included patients with infections caused by other 
HCV genotypes or both rapid and slow responders were 
included if they provided enough data for reanalysis 
of  the  data  for  the  subset  of  slow  responders  with 
HCV  genotype  1  infection.  Studies  were  excluded  if 
the patients: (1) had decompensated liver disease, (2) 
were seropositive for HIV or HBV markers and, (3) had 
significant co-morbidities such as decompensated liver 
disease, autoimmune diseases, hemoglobinopathies, and 
chronic kidney disease, (4) received low-dose ribavirin 
or peginterferon during some parts of their treatment 
period, and (5) had negative PCR findings at week 4 of 
treatment.
3.5. Methodological Quality Assessment of RCTs
The methodological quality, defined as the confidence 
that the design and reporting of a trail will restrict the 
possibility  of  a  bias  in  intervention  comparison,  was 
evaluated as previously reported (14). The only difference 
was  that  the  blinding  of  patients  or  investigators 
was  not  feasible  in  the  current  study  because  of  the 
different  treatment  durations.  Allocation  sequence Hepat Mon. 2011;11(8):612-619
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generation and concealment were obtained as measures 
of bias control. The allocation sequence generation was 
considered adequate if it was obtained through a table- 
or computer-generated random numbers. The allocation 
concealment  was  considered  adequate  if  the  patients 
were randomized by a central independent unit or by 
using serially numbered   opaque sealed envelopes. 
3.6. Data Synthesis
All  analyses  were  performed  using  the  Mix  2.0 
professional  software  for  meta-analysis  with  Excel 
(15). Data on all patients were included on the basis of 
intention-to-treat principle, irrespective of compliance 
or follow-up. To manage the missing data, we performed 
a worst case scenario analysis. However, since we had a 
positive outcome (virological response), all missing data 
were considered as data from the non-responders. The 
results are presented as relative risk ratio (RR) with 95% 
confidence interval (CI). The meta-analysis was performed 
using the DerSimonian and Laird random effects model. 
The random effects model provides a highly conservative 
estimate of significance. This model operates under 
the assumption that the included studies are only a 
random sample of all studies. Hence, heterogeneity 
between individual studies will result in a wider CI of 
the  summary  estimate.  The  summary  estimate  was 
calculated as an average of the individual study results 
weighted by the inverse of their variance by using the 
DerSimonian and Laird random effects model (16). The 
estimate of heterogeneity was obtained from Q statistics. 
The study findings were considered heterogeneous if the 
resultant P-value was less than 0.1 (17). Furthermore, I2 was 
used to provide a measure of the degree of inconsistency 
between the results of the studies. Its value describes the 
percentage of total variation across studies that is caused 
by heterogeneity rather than chance. The I2 value lies 
between 0% and 100%. A value of 0% indicates no observed 
heterogeneity, whereas larger values indicate increasing 
heterogeneity  (18).  Publication  bias  was  assessed  by 
testing for funnel plot asymmetry by using Harbord’s 
modified test. Several statistical tests can be used to 
evaluate funnel plot asymmetry. However, among these 
tests, a regression-based approach is most appropriate 
for detecting significant publication bias. For analyzing 
binary outcomes, the Harbord’s modified test is preferred 
over Egger’s test because Harbord’s modified test has a 
lower  likelihood  of  showing  false-positive  results  due 
to the mathematical association between logRR and its 
standard error (19). 
3.7. Transparency Declarations
The authors declare that there are no conflicts of 
interest, financial or otherwise regarding the contents 
of this review. Furthermore, this meta-analysis was not 
supported by any pharmaceutical company, government 
agency, or grants from other sources.
4. Results
4.1. Results of the Search
Our search strategy yielded 452 unique citations. Figure 1 
shows our search analysis protocol. We discarded 415 non-
relevant records and retrieved full texts of 37 potentially 
relevant papers. We excluded: 10 reviews regarding the 
optimal treatment of infections caused by different HCV 
genotypes  (20-29),  1  case  series  with  9  subjects  (30),  3 
studies that evaluated 24- vs. 48-week treatment of HCV 
genotype  1  infection  in  patients  showing  RVR  (12,  31, 
32), 1 study that compared rapid responders with slow 
responders (33). Furthermore, we excluded 1 letter (34), 
5 studies on long-term therapy with standard interferon 
(35-39), 3 studies on HCV/HIV co-infected patients (40-
42), 2 non-randomized studies (43, 44), 1 study in which 
patients  in  the  extended  therapy  group  were  treated 
with low dose peginterferon or ribavirin (45). We also 
excluded 1 study on slow responders with HCV genotype 
2/3 infection, 1 study that treated the slow responders by 
administration of triple therapy with histamine as a part 
of or throughout the subjects’ treatment duration (46), 
and 1 study with patients randomized at the baseline but 
not according to RVR and EVR (47). Ultimately, 7 studies 
that met our criteria were included (48-54). 
4.2. Included Studies
One study was from Japan, 2 from Spain, and one from 
each of Austria, the US, Italy, and Germany. All studies 
were  published  as  full  texts  in  peer-reviewed  journals 
Authors Origin of 
Samples 
Randomization Allocation Concealment Naive Type of Peginterferon
Mangia et al., 2008, (48) Italy Adequate Adequate Yes  2a/2b
Berg et al., 2006, (49) Germany Unclear Unclear Yes 2a
Ferenci et al., 2010, (50) Austria Unclear Unclear Yes 2a
Pearlman et al., 2007, (51) US Adequate Adequate Yes 2b
Sanchez-Tapias et al., 2006, (52) Spain partially Inadequate Yes 2a
Miyase et al., 2010, (53) Japan Unclear unclear NR a 2b
Buti et al., 2010, (54) Spain Adequate Adequate Yes 2b
Table 1. Characteristics and Results of Methodological Quality Assessment of the Included Studies
a Abbreviation: NR, not reportedHepat Mon. 2011;11(8):612-619
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from 2005 to 2010. One study, by Sanchez-Tapias et al., 
was  partially  randomized.  Methodological  quality 
factorsincluding random sequence generation and 
allocation concealment were not provided in the reports 
by Ferenci et al., Miyase et al., and Berg et al. One report by 
Miyase et al. was in Japanese. We excluded some patients 
from the relevant studies. From the study reported by 
Ferenci et al., 262 subjects were excluded because they 
showed RVR or because of the lack of randomization in 
the study for the duration of therapy, and 28 subjects 
were excluded because of infection with HCV genotype 
4.  35  subjects  with  non-genotype  1  infection  and  184 
with RVR were excluded from the Sanchez-Tapias study 
and 185 subjects with RVR and 128 patients who were not 
slow responders were excluded from the study reported 
by Mangia et al. From the study reported by Berg et al. 
81  subjects  were  excluded  because  they  showed  RVR 
and 168 were excluded because of lack of information 
about whether they were slow responders. Ultimately, 
1206 subjects, 631 of whom received extended therapy, 
were  included  in  the  meta-analysis.  SVR  was  similarly 
defined  across  all  studies  as  the  lack  of  RVR  along 
with achieving an undetectable PCR or at least a 2-log 
decrement in the HCV-RNA levels from baseline after 12 
Authors
          Men, %             Age, y            ALT b, IU/L       Viral load, IU/mL
Cirrhosis, 
F3/F4, %
72 wk 48 wk 72 wk 48 wk 72 wk 48 wk 72 wk 48 wk
72 
wk
48 
wk
Ferenci et al. 65 64 44.3 ± 10.2 c 45.1 ± 10.6 c 93.3 ± 62.7 c 91.9 ± 74.7 c 700 (K d) 650 (K) 19 20
Pearlman et al. 65 67 54 56 NR b NR 5400 (K) 5300 (K)  25 27
Nagaki et al. 67 62 54 62 52 64 ≥ 1500 (K) 67% ≥ 1500 (K) 77% 77 62
Sanchez-Tapias 
et al.
63 69 43.2 ± 10.2 c 42.8 ± 9.9 c 2.7 ± 1.6 c ULN b 2.4 ±1.3 c ULN 1110 ± 1333 c (K) 963 ± 1153 c (K) NR  NR
Buti et al. 63 60 46.5 ± 11.6 c 44.5 ± 9.9 c 85 ± 71 c 76 ± 48 c > 800 (K) 93.2% > 800 (K) 87.2% NR NR
Miyase et al. 33 58 83 2243 (K) NR
Table 2. Characteristics of the Patients in the Included Studies a
a In the study by Mangia et al. 44% of the patients were excluded, so the data provided by authors could not be considered representative for the  characteristics 
of the included patients. 
b Abbreviations: ALT, Antiretroviral therapy; NR, Not reported; ULN, Upper limit of normal
c Value ± SD
d K: 103
Adverse event Patients, No. OR (95% CI)
Heterogeneity Assessment
Q (K) P I 2
Neutropenia/leukopenia 1571 1 (0.71–1.41) 1.34 (5) 0.85 0%
Thrombocytopenia 326 0.61 (0.29–1.25)
Fever 485 1.03 (0.69–1.54) 0 (1) 0.96 0%
Asthenia 485 0.96 (0.66–1.38) 0.06 (1) 0.81 0%
Headache 485 1.06 (0.72–1.56) 0.21 (1) 0.65 0%
Flu-like symptoms 485 0.89 (0.51–1.56) 1.85 (1) 0.17 46%
Anemia 1412 1.06 (0.72–1.56) 2.7 (3) 0.44 0%
Depression 615 0.95 (0.12–7.39) 2.14 (1) 0.14 53%
Voluntary therapy discontinuation  1571 2.70 (1.60–4.56) 4.15 (4) 0.39 4%
Therapy discontinuation due to safety reasons 1470 1.54 (1.11–2.14) 0.22 (3) 0.97 0%
Table 3. Comparative Safety Profile of the 72-Week and 48-Week Anti-HCV Therapies with Peginterferon and Ribavirin
37 full-text articles were assessed for
eligibility
452 records were screened
136 duplicates were removed
588 records were identiﬁed through
database searching
7 studies were included in quantitative
synthesis (meta-analysis)
415 records were excluded
7 studies were included in qualitative
synthesis
Figure 1. Search Result AnalysisHepat Mon. 2011;11(8):612-619
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weeks  or  undetectable  HCV-RNA  levels  after  24  weeks. 
Table 1  shows  some  characteristics  of  the  included 
studies. All trials had similar inclusion criteria. Chronic 
hepatitis C was diagnosed on the basis of the presence 
of HCV-RNA in the blood, elevated plasma transaminase 
levels for at least 6 months, and evidence of chronic viral 
hepatitis on performing a pretreatment liver biopsy. 
The exclusion criteria were also very similar in all the 
trials  and  consisted  of  decompensated  liver  disease; 
autoimmune  mediated  diseases;  chronic  hepatitis  B; 
significant  co-morbidities  such  as  HIV,  kidney  disease, 
cardiovascular disease, psychiatric illnesses, or history of 
hospitalization for major depression; poorly controlled 
diabetes;  prior  organ  transplantation;  seizures  or 
brain injury requiring medication for stabilization; or 
hematological diseases with anemia, low platelet count, 
or neutropenia. Pregnant or breast-feeding women were 
also excluded from the study. 
4.3. Characteristics of the Patients
Patients’ characteristics are presented in Table 2. Miyase 
et al.  reported  their  patients’  baseline  data  according 
to the virological responses but not according to the 
treatment groups. Sanchez-Tapias et al. did not report 
the percentages of patients with extensive fibrosis (stage 
F3/F4), and Pearlman did not report the patients’ baseline 
levels  of  liver  enzymes.  In  the  study  by  Mangia  et al. 
44% of the total studied patients were excluded, so the 
data provided by the authors could not be considered 
representative of the characteristics of the included 
patients. 
4.4. Comparison of SVR Achieved during the 72-week 
Therapy with that Achieved with the Standard 48-week 
Therapy
The  slow  virological  responders  who  received  the 
72-week  anti-HCV  therapy  had  a  significantly  higher 
likelihood of achieving SVR than their counterparts who 
received the standard 48-week anti-HCV therapy [RR = 1.44 
(95% CI 1.20–1.74)]. The heterogeneity in funnel plots was 
not significant (P = 0.19), and the actual heterogeneity 
between  study  results  that  could  not  be  justified  by 
chance  alone  was  30%  (I2). Furthermore, Tau-squared 
value was 0.01 (95% CI, 0–0.09). Figure 2 shows summary 
estimates with their 95% CI for each study along with 
the weighted-pooled estimate. Figure 3 shows results of 
the exclusion sensitivity analysis. The pooled result was 
evidently robust and did not rely on any single study 
result. The assessment of publication biases by using 
Harbord’s modified test showed a non-significant P value 
(P = 0.11). Moreover, the P value for Egger’s test was 0.59. 
Figure 4 shows Harbord’s regression line. 
4.5. Comparison of the Safety of the 72-week Therapy 
with that of the Standard 48-week Therapy
Figure 2. Summary Estimate with 95% Confidence Interval for Relative Risk (RR) of Sustained Virological Responses (SVR) Rates Achieved with 72- vs. 48-week 
Treatment of Hepatitis C  Virus (HCV) Infection with Peginterferon and Weight-Based Ribavirin
a RR, relative riskHepat Mon. 2011;11(8):612-619
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The information about the safety profiles of the 72-
week therapy vs. the standard 48-week therapy was not 
well  elucidated.  Table 3  shows  the  pooled  estimate  of 
comparative safety and number of patients included 
in the analyses. Due to the low number of patients and 
lack of data on adequate reporting of safety, the evidence 
on the comparative safety of the 72-week and 48-week 
therapies is not robust. Although none of the differences 
in  the  individual  adverse  effects  reached  statistical 
significance, the number of patients who discontinued 
the  therapy  due  to  safety  concerns  or  voluntarily  was 
considerably greater among the patients who received 
the 72-week therapy. 
5. Discussion 
In this systematic review, we assessed the comparative 
efficacy  of  anti-HCV  therapy  with  peginterferon  alpha 
and  weight-based  ribavirin  for  durations  of  72  weeks 
and 48 weeks in slow virological responders with HCV 
genotype  1  infection  who  were  seronegative  for  HIV 
and  HBV  co-infections.  Our  results  suggest  that  the 
72-week  treatment  helped  in  achieving  a  significantly 
higher  SVR  rate  than  the  48-week  treatment  in  slow 
virological  responders  with  HCV  genotype  1  infection. 
Because of the high mean viral load of the included 
patients, our findings can easily be extrapolated to the 
slow virological responders with high viral load of HCV 
genotype 1 or hard to treat HCV infections. Although 
the  differences  among  any  individual  adverse  effects 
were  not  statistically  significant,  voluntary  treatment 
discontinuation or discontinuation because of safety 
reasons was significantly greater in the 72-week treatment 
group. This finding can be attributed to longer or severer 
adverse effects in the extended therapy group. The SVR 
rate achieved with the 72-week therapy can be increased 
by  encouraging  the  patients  to  complete  the  72-week 
therapy, closely following-up the patients’ condition, and 
reducing the treatment discontinuations by managing 
the adverse effects.
We  are  highly  confident  of  the  effectiveness  of  our 
finding for the following reasons: (1) we considered non-
significant heterogeneity test results despite clinical 
heterogeneity  across  studies  including  (a)  different 
treatment protocols for ribavirin therapy, (b) inclusion 
of some patients with previous history of treatment, (c) 
different peginterferon type, and (d) different ethnicity 
of the subjects; (2) we found robust results that were 
confirmed  by  exclusion  sensitivity  analysis,  which 
showed that the final estimate was not dependent on 
any single study results (Figure 4); and (3) we performed 
non-significant publication assessment. The empirical 
evidence suggests that trials that fail to refute the null 
hypothesis have low odds of being published, especially 
those that are not funded by the industry (55, 56). Our 
publication bias assessment did not revealed such 
finding. Trim-and-fill method used to account for the 
missing data showed results similar to the findings of 
our original pooled estimate [RR = 1.29 (95% CI 1.13–1.47)] 
(4). Of seven included studies, 6 studies had complete 
and  1  had  partial  randomized  design.  Moreover,  the 
robust results of our sensitivity analysis suggest that 
both naive and treated patients can benefit from the 
extended therapy.
The greatest limitation in this review was insufficient 
reporting of safety data and methodological qualities of 
the RCTs. Therefore, we recommend that investigators 
of future trials adhere to the Consolidated Standards for 
Reporting  of  Trials  (CONSORT)  to  improve  the  quality 
of trial reports (57). Another limitation of our work was 
that the long-term clinical advantage of extended anti-
HCV treatment for HCC, decompensated liver disease, 
and cirrhosis could not be clarified. Furthermore, there 
are some concerns about the validity of our findings 
outside of a clinical trial setting. Our analysis showed 
Figure 3. Exclusion Sensitivity Plot
a RR, relative risk
Figure 4. Harbord’s Regression Line for Publication Bias Assessment
E
ff
i
c
i
e
n
t
 
S
c
o
r
e
 
/
 
F
i
s
h
e
r
 
I
n
f
o
r
m
a
t
i
o
nHepat Mon. 2011;11(8):612-619
618 Optimal Duration of Anti-HCV Treatment in Genotype 1 Alavian SM et al.
that the 72-week treatment course is difficult to tolerate 
for  most  patients  and  there  is  a  high  likelihood  of 
premature withdrawal. The odds ratio of 2.7 for voluntary 
therapy discontinuation in Table 3 supports this 
perspective. Therefore, in routine clinical practice and 
outside of a clinical trial setting, this rate of treatment 
discontinuation can become even higher to an extent 
that can reduce the rate of SVR. Low external validity of 
the findings of this review cannot be attributed to the 
reliability of our findings, but to the nature of the clinical 
trials included in the review. We suggest that making 
decision to extend the treatment course should be made 
on an individually basis and according to the patients’ 
tolerance during the first 48 weeks of therapy. Although 
the number of patients who discontinued the treatment 
because of safety reasons or personal causes was high in 
the extended therapy group, our meta-analysis showed 
that the 72-week therapy with peginterferon and ribavirin 
is significantly superior to the standard 48-week therapy 
for slow responders with genotype 1 infection.
Acknowledgements
None declared.
Financial Disclosures
None declared.
Funding/Support
None declared.
References 
1.  Ahmadipour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis 
C Virus Genotypes. Hepat Mon. 2005;5(3):77-82.
2.  Arens M. Clinically relevant sequence-based genotyping of HBV, 
HCV, CMV, and HIV. J Clin Virol. 2001;22(1):11-29.
3.  Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29 
(Suppl 1):74-81.
4.  Seeff  LB.  Natural  history  of  chronic  hepatitis  C.  Hepatology. 
2002;36(5 Suppl 1):S35-S46.
5.  Berenguer  J,  Alvarez-Pellicer  J,  Martin  PM,  Lopez-Aldeguer  J, 
Von-Wichmann  MA,  Quereda  C,  et  al.  Sustained  virological 
response to interferon plus ribavirin reduces liver-related 
complications and mortality in patients coinfected with human 
immunodeficiency virus and hepatitis C virus. Hepatology. 
2009;50(2):407-13.
6.  Singal  AK,  Singh  A,  Jaganmohan  S,  Guturu  P,  Mummadi  R, 
Kuo YF, et al. Antiviral therapy reduces risk of hepatocellular 
carcinoma in patients with hepatitis C virus-related cirrhosis. 
Clin Gastroenterol Hepatol. 2010;8(2):192-9.
7.  Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt 
B, Clavien PA. Systematic review and meta-analysis of interferon 
after curative treatment of hepatocellular carcinoma in patients 
with viral hepatitis. Br J Surg. 2009;96(9):975-81.
8.  Poynard  T,  McHutchison  J,  Manns  M,  Trepo  C,  Lindsay  K, 
Goodman Z, et al. Impact of pegylated interferon alfa-2b and 
ribavirin on liver fibrosis in patients with chronic hepatitis C. 
Gastroenterology. 2002;122(5):1303-13.
9.  Miyake  Y,  Takaki  A,  Iwasaki  Y,  Yamamoto  K.  Meta-analysis: 
interferon-alpha prevents the recurrence after curative 
treatment of hepatitis C virus-related hepatocellular carcinoma. 
J Viral Hepat. 2010;17(4):287-92.
10.  Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem 
S. Rapid virological response is the most important predictor 
of sustained virological response across genotypes in patients 
with chronic hepatitis C virus infection. J Hepatol. 2011;55(1):69-
75.
11.  Reau  N,  Satoskar  R,  Te  H,  DeVoss  A,  Elsen  C,  Reddy  G,  et  al. 
Evaluation of early null response to pegylated interferon and 
ribavirin as a predictor of therapeutic nonresponse in patients 
undergoing treatment for chronic hepatitis C. Am J Gastroenterol. 
2011;106(3):452-8.
12.  Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid 
virological response and treatment duration for chronic 
hepatitis C genotype 1 patients: a randomized trial. Hepatology. 
2008;47(6):1884-93.
13.  Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal 
length of antiviral therapy in patients with hepatitis C virus 
genotypes 2 and 3: a meta-analysis. Antivir Ther. 2009;14(8):1139-
48.
14.  Gluud LL. Bias in clinical intervention research. Am J Epidemiol. 
2006;163(6):493-501.
15.  Bax L, Yu LM, Ikeda N, Tsuruta H, Moons KG. Development and 
validation of MIX: comprehensive free software for meta-analysis 
of causal research data. BMC Med Res Methodol. 2006;6:50.
16.  Borenstein M, Hedges LV. Introduction to Meta-Analysis. the first 
ed. UK: John Wiley & Sons, Ltd; 2009.
17.  Petitti DB. Meta-Analysis, Decision Analysis, and Cost-Effectiveness 
Analysis: Methods for Quantitative Synthesis in Medicine. 2nd ed. 
New York: Oxford University Press; 2000.
18.  Higgins  JP,  Thompson  SG,  Deeks  JJ,  Altman  DG.  Measuring 
inconsistency in meta-analyses. BMJ. 2003;327(7414):557-60.
19.  Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study 
effects in meta-analyses. Stata J. 2009;9(2):197-210.
20.  Heathcote J. Retreatment of chronic hepatitis C: who and how? 
Liver Int. 2009;29(Suppl 1):49-56.
21.  Dieterich DT, Rizzetto M, Manns MP. Management of chronic 
hepatitis  C  patients  who  have  relapsed  or  not  responded 
to pegylated interferon alfa plus ribavirin. J Viral Hepat. 
2009;16(12):833-43.
22.  Nakamura J, Toyabe SI, Aoyagi Y, Akazawa K. Economic impact 
of  extended  treatment  with  peginterferon  alpha-2a  and 
ribavirin for slow hepatitis C virologic responders. J Viral Hepat. 
2008;15(4):293-9.
23.  Pearlman BL. Extended-therapy duration for chronic hepatitis 
C, genotype 1: the long and the short of it. World J Gastroenterol. 
2008;14(23):3621-7.
24.  Tarantino  G,  Craxi  A.  Optimizing  the  treatment  of  chronic 
hepatitis due to hepatitis C virus genotypes 2 and 3: a review. 
Liver Int. 2009;29(Suppl 1):31-8.
25.  Poordad FF. Review article: the role of rapid virologic response in 
determining treatment duration for chronic hepatitis C. Aliment 
Pharmacol Ther. 2010;31(12):1251-67.
26.  Poordad F, Reddy KR, Martin P. Rapid virologic response: a new 
milestone in the management of chronic hepatitis C. Clin Infect 
Dis. 2008;46(1):78-84.
27.  Pearlman BL. Chronic hepatitis C therapy: changing the rules of 
duration. Clin Gastroenterol Hepatol. 2006;4(8):963-71.
28.  Nguyen-Khac E, Capron D, Castelain S, Francois C, Braillon A. 
Personalized therapy for chronic viral hepatitis C in the naive 
patient: How can we optimize treatment duration as a function 
of viral genotype? Eur J Intern Med. 2007;18(7):510-5.
29.  Marcellin P, Heathcote EJ, Craxi A. Which patients with genotype 
1 chronic hepatitis C can benefit from prolonged treatment with 
the ‘accordion’ regimen? J Hepatol. 2007;47(4):580-7.
30.  Buti M, Valdes A, Sanchez-Avila F, Esteban R, Lurie Y. Extending 
combination therapy with peginterferon alfa-2b plus ribavirin 
for genotype 1 chronic hepatitis C late responders: a report of 9 
cases. Hepatology. 2003;37(5):1226-7.
31.  Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated 
interferon-alpha-2a plus ribavirin for treatment-naive Asian 
patients with hepatitis C virus genotype 1 infection: a multicenter, 
randomized controlled trial. Clin Infect Dis. 2008;47(10):1260-9.
32.  August-Jorg  BSE,  Borovicka  J,  Dufour  JF,  Gonvers  JJ,  Henz  S, 
Hermann R, et al. Twenty-four vs. forty-eight weeks of re-therapy Hepat Mon. 2011;11(8):612-619
619 Optimal Duration of Anti-HCV Treatment in Genotype 1 Alavian SM et al.
with  interferon  alpha  2b  and  ribavirin  in  interferon  alpha 
monotherapy relapsers with chronic hepatitis C. Swiss Med Wkly. 
2003;133(33-34):455-60.
33.  Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi 
M, et al. Short-term prolongation of pegylated interferon and 
ribavirin therapy for genotype 1b chronic hepatitis C patients 
with early viral response. Hepatol Res. 2009;39(8):753-9.
34.  Hézode C. Treatment extension to 72 weeks of peginterferon and 
ribavirin  in  hepatitis  C  genotype  1-infected  slow  responders. 
Hepato Gastro. 2008;15(3):252-3.
35.  Yao GB, Ji YY, Xu DZ, Gao J, Wu XH, Zhang QB, et al. Long-term 
efficacy of recombinant interferon alpha 2a in the treatment of 
chronic hepatitis C: A randomized prospective study comparing 
two  dose  schedules  in  Chinese  patients.  Hepato Gastro. 
1999;46(26):1059-64.
36.  Yao G, Ji Y, Yang M, Xu D, Gao J, Wu X, et al. Long-term efficacy 
of recombinant Interferon alpha 2a in the treatment of chronic 
hepatitis C : A randomized prospective study comparing two dose 
schedules in Chinese patients. Chinese Med J. 1998;111(10):922-6.
37.  Piccinino F, Felaco FM, Sagnelli E, Aprea L, Messina V, Pasquale 
G, et al. Long-term lymphoblastoid interferon-alpha therapy 
for non-cirrhotic chronic hepatitis C: an Italian multicentre 
study on dose and duration of IFN alpha treatment. Res Virol. 
1998;149(5):283-91.
38.  Fattovich  G,  Zagni  I,  Fornaciari  G,  Minola  E,  Fabris  P,  Boccia 
S, et al. Efficacy of prolonged 5 million units of interferon in 
combination with ribavirin for relapser patients with chronic 
hepatitis C. J Viral Hepat. 2003;10(2):111-7.
39.  Arase Y, Ikeda K, Tsubota A, Suzuki Y, Saitoh S, Kobayashi M, et 
al. Efficacy of prolonged interferon therapy for patients with 
chronic hepatitis C with HCV-genotype 1b and high virus load. 
J Gastroenterol. 2003;38(2):158-63.
40.  Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, 
Ocampo  A,  et  al.  Role  of  weight-based  ribavirin  dosing  and 
extended  duration  of  therapy  in  chronic  hepatitis  C  in  HIV-
infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 
2007;23(8):972-82.
41.  Fuster D, Planas R, Gonzalez J, Force L, Cervantes M, Vilaro J, et 
al. Results of a study of prolonging treatment with pegylated 
interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients 
with no early virological response. Antivir Ther. 2006;11(4):473-
82.
42.  Angeli E, Mainini A, Cargnel A, Uberti-Foppa C, Orani A, Carbone 
R, et al. Predictability of sustained virological response to 
pegylated interferon alpha-2b Plus ribavirin therapy by week-8 
viral response in HIV-positive patients with chronic hepatitis C 
virus infection. Curr HIV Res. 2009;7(4):447-55.
43.  Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki 
H, et al. A matched case-controlled study of 48 and 72 weeks 
of peginterferon plus ribavirin combination therapy in 
patients infected with HCV genotype 1b in Japan: amino acid 
substitutions in HCV core region as predictor of sustained 
virological response. J Med Virol. 2009;81(3):452-8.
44.  Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto 
E, et al. Prolonged treatment with pegylated interferon alpha 
2b plus ribavirin improves sustained virological response in 
chronic hepatitis C genotype 1 patients with late response in a 
clinical real-life setting in Japan. Hepatol Res. 2009.
45.  Nagaki M, Shimizu M, Sugihara JI, Tomita E, Sano C, Naiki T, et 
al. Clinical trial: extended treatment duration of peginterferon-
alpha2b  plus  ribavirin  for  72  and  96  weeks  in  hepatitis  C 
genotype 1-infected late responders. Aliment Pharmacol Ther. 
2009;30(4):343-51.
46.  Zeuzem S, Pawlotsky JM, Lukasiewicz E, von Wagner M, Goulis I, 
Lurie Y, et al. International, multicenter, randomized, controlled 
study comparing dynamically individualized versus standard 
treatment  in  patients  with  chronic  hepatitis  C.  J Hepatol. 
2005;43(2):250-7.
47.  Ide T, Hino T, Ogata K, Miyajima I, Kuwahara R, Kuhara K, et al. 
A randomized study of extended treatment with peginterferon 
alpha-2b plus ribavirin based on time to HCV RNA negative-
status in patients with genotype 1b chronic hepatitis C. Am J 
Gastroenterol. 2009;104(1):70-5.
48.  Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta 
V, et al. Individualized treatment duration for hepatitis C 
genotype 1 patients: A randomized controlled trial. Hepatology. 
2008;47(1):43-50.
49.  Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach 
T, et al. Extended treatment duration for hepatitis C virus type 
1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus 
ribavirin. Gastroenterology. 2006;130(4):1086-97.
50.  Ferenci P, Laferl H, Scherzer TM, Maieron A, Hofer H, Stauber R, et 
al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis 
C  genotypes  1  and  4  patients  with  slow  virologic  response. 
Gastroenterology. 2010;138(2):503-12, 12 e1.
51.  Pearlman  BL,  Ehleben  C,  Saifee  S.  Treatment  extension  to  72 
weeks of peginterferon and ribavirin in hepatitis c genotype 
1-infected slow responders. Hepatology. 2007;46(6):1688-94.
52.  Sanchez-Tapias  JM,  Diago  M,  Escartin  P,  Enriquez  J,  Romero-
Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 
48 versus 72 weeks in patients with detectable hepatitis C virus 
RNA at week 4 of treatment. Gastroenterology. 2006;131(2):451-
60.
53.  Miyase  S,  Ogata  K,  Haraoka  K,  Morishita  Y,  Fujiyama  S.  The 
efficacy of prolonging treatment with peginterferon alfa-2b and 
ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients 
HCV RNA positive at week 8 but negative at week 12. Acta Hepato 
Jpn. 2010;51(1):48-50.
54.  Buti M, Lurie Y, Zakharova NG, Blokhina NP, Horban A, Teuber G, 
et al. Randomized trial of peginterferon alfa-2b and ribavirin for 
48 or 72 weeks in patients with hepatitis C virus genotype 1 and 
slow virologic response. Hepatology. 2010;52(4):1201-7.
55.  Hopewell  S,  Loudon  K,  Clarke  MJ,  Oxman  AD,  Dickersin  K. 
Publication bias in clinical trials due to statistical significance 
or direction of trial results. Cochrane Database Syst Rev. 
2009(1):MR000006.
56.  Turner  EH,  Matthews  AM,  Linardatos  E,  Tell  RA,  Rosenthal  R. 
Selective publication of antidepressant trials and its influence 
on apparent efficacy. N Engl J Med. 2008;358(3):252-60.
57.  Moher D, Jones A, Lepage L. Use of the CONSORT statement and 
quality of reports of randomized trials: a comparative before-
and-after evaluation. JAMA. 2001;285(15):1992-5.